GlaxoSmithKline Will Buy Arixtra, Fraxiparine In Event Of Sanofi/Aventis Merger

GSK would pay $541 mil. for the two anti-thrombotic agents and a manufacturing facility in France. The sale represents a preemptive divestiture on Sanofi's part; both products compete with Aventis' Lovenox.